Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses

Neuroendocrinology Letters

Volumn 32, Issue 5, 2011, Pages 667-670

  Zedkova, Iveta ^a   Dudova, Iva ^a   Urbanek, Tomas ^b   Hrdlicka, Michal ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b PSYCHOLOGICKÝ ÚSTAV AV CR   (Czech Republic)

Author keywords

Adolescence; Antipsychotics; Onset of action; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

ADOLESCENT; ARTICLE; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL RECORD REVIEW; SCHIZOPHRENIA;

EID: 84857436691     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Agid O, Kapur S, Warrington L, Loebel A, Siu C (2008). Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res. 102: 241-248.
2. Bares M, Novak T, Kopecek M, Stopkova P, Sos P (2009). Is combined treatment more effective than switching to monotherapy in patients with resistant depression? A retrospective study. Neuroendocrinol Lett. 30: 723-728.
3. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. (1998). Risperidone versus clozapine in the treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry. 155: 499-504. (Pubitemid 28207445)
4. Conley RR, Mahmoud R (2001). A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 158: 765-774. (Pubitemid 32429846)
5. Gerlach J, Peacock L (1995). New antipsychotics: the present status. Int Clin Psychopharmacol. 10 (Suppl.3): 39-48. (Pubitemid 26056451)
6. Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H (1994). Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog. Neuropsychopharmacol. Biol Psychiatry. 18: 129-137.
7. Hrdlicka M, Zedkova I, Blatny M, Urbanek T (2009). Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: a retrospective study. Neuroendocrinol Lett. 30: 256-261.
8. Kasper S, Rosillon D, Duchesne I (2001). Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol. 16: 179-87. (Pubitemid 32612515)
9. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzales C, Rupnow MFT, et al. (2006). A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 85: 254-265. (Pubitemid 43947539)
10. Potkin SG, Cohen M, Panagides J (2007). Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 68: 1492-1500. (Pubitemid 350073395)
11. Sacchetti E, Valsecchi P, Parrinello G (2008). A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. Schizophr Res. 98: 55-65. (Pubitemid 350245584)
12. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L (2009). Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 110: 80-89.
13. Sadock BJ, Sadock VA, editors (2005). Kaplan Sadock's Comprehensive Textbook of Psychiatry. Philadelphia: Lippincott Williams & Wilkins.
14. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA (2004). A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 29: 133-145. (Pubitemid 38068023)
15. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004). Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 161: 1837-1847. (Pubitemid 39314678)
16. Thase ME (2001). Methodology to measure onset of action. J Clin Psychiatry. 62 (suppl 15): 18-21.
17. Thompson C (2002). Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol Clin Exp. 17: S27-S32.
18. World Health Organization (1992). International Classification of Diseases, 10th ed. Geneva: WHO.
19. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al (2006). Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology. 186: 572-578.
20. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA (2006). Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry. 67: 1093-1103. (Pubitemid 44230881)
21. Zimbroff D, Warrington L, Loebel A, Yang R, Siu C (2007). Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol. 22: 363-370. (Pubitemid 47530841)